Human monoclonal antibodies for discovery, therapy, and vaccine acceleration.

Human monoclonal antibodies for discovery, therapy, and vaccine acceleration. Curr Opin Immunol. 2019 Aug 23;59:130-134 Authors: Andreano E, Seubert A, Rappuoli R Abstract Screening of single B cells from convalescent or vaccinated people allows the discovery of novel targets for infectious diseases and rapid production of engineered human monoclonal antibodies (mAbs) that can prevent or control infections by passive immunization. Here we propose that the development of human mAbs can also significantly accelerate vaccine development by anticipating some of the key biological and regulatory questions. PMID: 31450054 [PubMed - as supplied by publisher]
Source: Current Opinion in Immunology - Category: Allergy & Immunology Authors: Tags: Curr Opin Immunol Source Type: research